$17.28
2.81% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Stock price

$17.28
-1.42 7.59% 1M
+9.00 108.70% 6M
+8.29 92.21% YTD
+7.78 81.89% 1Y
-13.87 44.53% 3Y
+2.91 20.25% 5Y
+4.28 32.92% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.50 2.81%
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key metrics

Market capitalization $1.50b
Enterprise Value $1.63b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.01
P/S ratio (TTM) P/S ratio 7.39
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -2.96%
Revenue (TTM) Revenue $203.45m
EBIT (operating result TTM) EBIT $-279.69m
Free Cash Flow (TTM) Free Cash Flow $-272.34m
Cash position $277.44m
EPS (TTM) EPS $-4.56
P/E forward negative
P/S forward 6.55
EV/Sales forward 7.10
Short interest 9.64%
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
203 203
3% 3%
100%
- Direct Costs 53 53
2% 2%
26%
150 150
3% 3%
74%
- Selling and Administrative Expenses 173 173
13% 13%
85%
- Research and Development Expense 214 214
11% 11%
105%
-236 -236
17% 17%
-116%
- Depreciation and Amortization 43 43
2% 2%
21%
EBIT (Operating Income) EBIT -280 -280
15% 15%
-137%
Net Profit -352 -352
12% 12%
-173%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Positive
Seeking Alpha
10 days ago
Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setbacks in FSGS trials, ongoing studies and FDA involvement suggest potential future approval, bolstered by proteinuria reduction as a validated surrogate endpoint. Financially, TVTX faces high operat...
Neutral
GlobeNewsWire
11 days ago
Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeuti...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 380
Founded 2008
Website www.travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today